Zacks Small Cap Comments on CEL-SCI Co.’s FY2024 Earnings (NYSE:CVM)

CEL-SCI Co. (NYSE:CVM) – Investment analysts at Zacks Small Cap lowered their FY2024 earnings per share estimates for shares of CEL-SCI in a research report issued on Monday, April 15th. Zacks Small Cap analyst J. Vandermosten now expects that the company will earn ($0.51) per share for the year, down from their previous estimate of ($0.48). The consensus estimate for CEL-SCI’s current full-year earnings is ($0.51) per share.

CEL-SCI (NYSE:CVM) last announced its quarterly earnings data on Wednesday, February 14th. The company reported ($0.14) earnings per share (EPS) for the quarter.

Separately, StockNews.com lowered CEL-SCI from a “hold” rating to a “sell” rating in a research report on Friday, March 15th.

CEL-SCI Price Performance

CVM stock opened at $1.52 on Wednesday. The business has a 50 day moving average price of $2.00 and a 200 day moving average price of $2.17. The stock has a market cap of $82.05 million, a price-to-earnings ratio of -2.24 and a beta of 1.29. CEL-SCI has a fifty-two week low of $1.04 and a fifty-two week high of $3.23. The company has a quick ratio of 0.78, a current ratio of 1.26 and a debt-to-equity ratio of 0.75.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. boosted its stake in shares of CEL-SCI by 9.4% in the fourth quarter. Vanguard Group Inc. now owns 2,079,624 shares of the company’s stock valued at $5,657,000 after buying an additional 178,478 shares in the last quarter. Forthright Family Wealth Advisory LLC purchased a new stake in shares of CEL-SCI in the fourth quarter valued at approximately $45,000. Virtu Financial LLC purchased a new stake in shares of CEL-SCI in the fourth quarter valued at approximately $163,000. Cantor Fitzgerald L. P. purchased a new stake in shares of CEL-SCI in the fourth quarter valued at approximately $329,000. Finally, Northern Trust Corp boosted its stake in shares of CEL-SCI by 7.2% in the fourth quarter. Northern Trust Corp now owns 83,864 shares of the company’s stock valued at $228,000 after buying an additional 5,629 shares in the last quarter. Institutional investors and hedge funds own 12.08% of the company’s stock.

About CEL-SCI

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.